Kathleen I. Pritchard, MD, FRCP | Authors

Adjuvant Endocrine Therapy for Breast Cancer: Longer Therapy and the Need for Personalized Treatment-Should We Treat Beyond the Data?

December 15, 2013

In the future, we also need to improve our ability to personalize the duration of endocrine therapy, with a goal of optimizing patient selection for extended therapy. Hopefully, clinical-pathologic indices and predictive biomarkers similar to the Oncotype DX 12-gene recurrence score or the PAM50 risk of recurrence score for adjuvant chemotherapy will soon emerge to guide adjuvant endocrine therapy.

Adjuvant Endocrine Therapy for Breast Cancer: A Commentary

June 15, 2012

The review by Drs. Ruta Rao and Melody Cobleigh in this issue of ONCOLOGY summarizes the state-of-the-art adjuvant hormonal therapy for breast cancer concisely and appropriately.

Adjuvant Hormonal Therapy for Premenopausal Breast Cancer: Incorporating Clinical Experience

April 15, 2010

The article “Adjuvant Hormonal Therapy in Premenopausal Women With Operable Breast Cancer: Not-So-Peripheral Perspectives” by Richard Love, published in this issue of ONCOLOGY,

Ovarian Suppression/Ablation in Premenopausal ER-Positive Breast Cancer Patients

January 01, 2009

Developed over a century ago,[1] endocrine therapy remains the most effective and the most clearly targeted form of systemic therapy for breast cancer. Endocrine treatments work best in women whose tumors are positive for estrogen receptors (ER) and/or progesterone receptors (PR).

Commentary (Wong/Pritchard): Adjuvant Hormonal Therapy in Early Breast Cancer

October 01, 2005

Breast cancer is a systemic diseasewith 10-year relapse risksafter surgery alone ranging between30% and 50%.[1] About 60%to 75% of breast cancers are hormonereceptor–positive[2] and are potentiallyresponsive to endocrine therapy,which remains a cornerstone in the adjuvanttherapy of such tumors in thisera of targeted therapy and genomics.

Commentary (Pritchard)-Obesity and Cancer: The Risks, Science, and Potential Management Strategies

June 01, 2005

This excellent summary of theassociation of overweight andobesity with increased incidenceand poorer prognosis in a varietyof cancers is well worth the reader'sattention. Dr. McTiernan presents literaturesuggesting that overweight isassociated with increased incidenceand mortality in a variety of types ofcancer. In the case of breast cancer,for which there are more data than anyother cancer site, the increased risk ofmortality appears to be in part relatedto increased incidence in postmenopausalwomen, and to a poorer prognosisassociated with both overweightand weight gain following diagnosis.

Managing the Risk of Osteoporosis in Women With a History of Early Breast Cancer

October 01, 2004

This excellent and practical articleby Dr. Ravdin is worthwhilereading for every physician involvedin the long-term care of womenwith a previous diagnosis of breastcancer. Dr. Ravdin clearly outlinesthe theoretical rationale underlying theincreased risk of osteopenia and osteoporosisin women with a history ofbreast cancer. The fact that such womencommonly undergo prematuremenopause either deliberately, as partof treatment for breast cancer, or as asecondary effect of chemotherapy, andthat estrogen-replacement therapywith or without progesterone remainscontraindicated for fear of increasingthe risk of recurrence, clearly contributesto the increased possibility ofdeveloping osteopenia or osteoporosis.New data supporting the role ofaromatase inhibitors in adjuvant therapy[

Current Management of Menopausal Symptoms in Cancer Patients

January 01, 2002

Barton, Loprinzi, and Gostout provide a comprehensive, accurate, and multidisciplinary review of the management of menopausal symptoms in patients with a previous diagnosis of cancer. The article is clearly enhanced by the authorship of individuals from different backgrounds, each of whom bring a valuable perspective to the subject. Additional attention to several issues would, however, make interpretation of the data on this subject, and hence, the management of patients with these problems, more clear.

Endocrine Therapy for Breast Cancer

April 01, 2000

In addition to ovarian ablation by means of surgery or irradiation, a wide variety of endocrine agents are now available for the management of breast cancer, in both the metastatic and adjuvant settings. Currently available

Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 6

June 01, 1999

Problem: Several million women worldwide have survived breast cancer but are currently advised against the use of estrogen for the management of menopausal symptoms and for the prevention of early cardiovascular death and osteoporosis.